SIRPA and neoplasm: In the DMPLAC/siD47 complex, bacterial lysate–modified DMPLAC acts as an immunostimulant, whereas siCD47 blocks the SIRP-α/CD47 pathway to improve the immunogenicity of tumor cells, making it easier for them to be cleared by immune cells activated by DMPLAC.